An apparatus and method is described for needle access of a surgically created vascular access for use as a means to receive hemodialysis and other procedures requiring vascular access and, more particularly, an apparatus and method for vascular access of an arteriovenous graft or arteriovenous fistula that enables location of cannulation sites post-implant.
Hemodialysis is a life-sustaining treatment for patients with end stage renal disease. Hemodialysis is a process whereby large amounts of blood are removed from the body, filtered through a machine that removes wastes, and then returned into the body.
A vascular access site on the body where blood will be removed and returned during dialysis is prepared before starting hemodialysis. Creation of an arteriovenous fistula (“AVF”) is achieved in a surgical procedure in which a vein is connected directly to an artery. The connection between the artery and the vein may be formed using an arteriovenous graft (“AVG”) made from a synthetic material and implanted just under the skin. Placement sites for AVG's include, without limitation, the forearm, upper arm, neck, chest, and thigh, in either straight or looped configurations. Once surgically positioned, an AVG becomes a conduit that can be used repeatedly for blood access during hemodialysis. Needles are used to cannulate the graft through the skin, directly puncturing the walls of the graft. In conventional hemodialysis, two cannulas are placed in the access graft, with one needle puncture being made in the graft wall in the arterial side and another needle puncture being made in the venous side. During dialysis, blood is withdrawn from the arterial side of the graft, passed through a hemodialysis machine, and then returned to the patient through the second needle inserted in the venous side of the graft.
A significant step in the hemodialysis procedure is “finding” the proper position within the graft to perform the needle sticks. Moreover, conventional dialysis protocols require a patient to undergo a dialysis procedure at least three times a week. As a result, the skin and underlying tissue are punctured numerous times per week to gain entry into the implanted AVG. The technique of cannulating an AVF or AVG for hemodialysis requires considerable skill. A vascular access often lies several centimeters below the surface of the skin and cannot be located by visual inspection. A medical technician is required to locate the AVF or AVG by palpation, which can prove to be extremely difficult. The punctures of the vascular access are prone to error and complication. Punctures done incorrectly may promote rupture of the access, bleeding, hematoma formation, pseudoaneurysm formation, severe pain or the development of organized thrombi within the lumen of the graft. The formation of such blood clots may result not only in multiple graft thromboses, but may eventually lead to graft failure. Missing the vascular access entirely or improperly positioning of the needle within the lumen of the AVF or AVG device are two contraindications, which adversely affect the time the graft remains patent. Locating the cannulation area simply by using conventional methods of palpating through the skin is sometimes unreliable.
For the forgoing reasons, there is a need for an apparatus and method for proper cannulation of a vascular access graft or fistula, including correct identification of an access region of the vascular access following implantation. The new apparatus should improve access to the implanted AVF or AVG device by allowing a user of the vascular access to facilitate accurate and reproducible entry into the implanted AVF or AVG of dialysis needles, cannulas, and the like, which are introduced into the vascular access via insertion through the skin.
An apparatus is provided for guiding cannulation with a dialysis needle of an arteriovenous dialysis access graft subcutaneously implanted in a body of a subject. The arteriovenous dialysis graft includes a flexible conduit defining a longitudinal flow passageway and has a first end portion configured to connect to an artery of the subject and a second end portion configured to connect to a vein of the subject such that blood flows through the longitudinal flow passageway of the conduit from the first end portion to the second end portion. A cannulation chamber defines a cannulation port, the conduit extending through the cannulation chamber for receiving the needle inserted through the cannulation port. The guiding apparatus comprises an elongated body member having a longitudinal axis and an inner surface. The body member comprises a base portion terminating in longitudinal edges. A distance between the longitudinal edges of the base portion is substantially equal to a lateral dimension of the cannulation chamber. Legs extend from the longitudinal edges of the base portion, the legs terminating in longitudinal edges. The base portion and legs define an open longitudinal channel for receiving the cannulation chamber. The body member is adapted to be secured adjacent the subcutaneous cannulation chamber such that the legs operatively engage the cannulation chamber for aligning the inner surface of the base portion with the cannulation port for guiding location of a needle insertion through the body member and into the cannulation chamber.
In one aspect, the body member has a first end and a second end, and wherein the body member is adapted to extend from the first end to the second end of the cannulation chamber. The body member may have at least one passage opening into the inner surface of the body member for passing a needle.
In another aspect, at least a portion of the cannulation chamber and the body member comprise a substantially magnetic or paramagnetic material.
In another embodiment, an apparatus is provided for guiding cannulation with a dialysis needle of an arteriovenous dialysis access graft subcutaneously implanted in a body of a subject. The arteriovenous dialysis graft includes a flexible conduit defining a longitudinal flow passageway and having a first end portion configured to connect to an artery of the subject and a second end portion configured to connect to a vein of the subject such that blood flows through the longitudinal flow passageway of the conduit from the first end portion to the second end portion. A cannulation chamber defines a cannulation port between the first end portion and the second end portion, the conduit extending through the cannulation chamber for receiving the needle inserted through the cannulation port. The guiding apparatus comprises an elongated tubular sleeve having a longitudinal axis. The sleeve defines an opening having a longitudinal dimension and a lateral dimension adapted to be substantially equal to a longitudinal dimension and a lateral dimension of the cannulation chamber. The sleeve is configured to accommodate the body of the subject adjacent the subcutaneous cannulation chamber of the access graft such that the opening surrounds the cannulation chamber for guiding location of a needle insertion into the cannulation port.
In one aspect, the material of the sleeve is selected from a film, paper, a woven fabric, or a non-woven fabric.
In still another embodiment, an apparatus is provided for guiding cannulation with a dialysis needle of an arteriovenous dialysis access graft subcutaneously implanted in a body of a subject. The arteriovenous dialysis graft includes a flexible conduit defining a longitudinal flow passageway and having a first end portion configured to connect to an artery of the subject and a second end portion configured to connect to a vein of the subject such that blood flows through the longitudinal flow passageway of the conduit from the first end portion to the second end portion. A cannulation chamber defines a cannulation port between the first end portion and the second end portion. The conduit extends through the cannulation chamber for receiving the needle inserted through the cannulation port. The guiding apparatus comprises an elongated body member having a longitudinal axis and an inner surface. The body member comprises a base portion terminating in longitudinal edges, a distance between the longitudinal edges of the base portion being substantially equal to a lateral dimension of the cannulation chamber. An elongated tubular sleeve has a longitudinal axis, the sleeve defining a pocket having a longitudinal dimension and a lateral dimension configured to receive the body member. The body member is adapted to be received in the pocket of the sleeve for securing adjacent the subcutaneous cannulation chamber such that the inner surface of the base portion is aligned with the cannulation port for guiding location of a needle insertion through the body member and into the cannulation chamber.
A kit is also provided and comprises at least one dialysis needle for accessing an arteriovenous dialysis access graft subcutaneously implanted in a body of a subject. The arteriovenous dialysis graft includes a flexible conduit defining a longitudinal flow passageway and having a first end portion configured to connect to an artery of the subject and a second end portion configured to connect to a vein of the subject such that blood flows through the longitudinal flow passageway of the conduit from the first end portion to the second end portion. A cannulation chamber defines a cannulation port, the conduit extending through the cannulation chamber for receiving the needle inserted through the cannulation port. A dispenser is provided for accommodating a plurality of elongated body members, each body member having a longitudinal axis and an inner surface. The body member comprises a base portion terminating in longitudinal edges, a distance between the longitudinal edges of the base portion being substantially equal to a lateral dimension of the cannulation chamber. The body member is adapted to be secured adjacent the subcutaneous cannulation chamber such that the legs operatively engage the cannulation chamber for aligning the inner surface of the base portion with the cannulation port for guiding location of a needle insertion. Each body member has at least one passage opening into the inner surface of the body member for passing a needle, the needle passage of the body member being in a different position than the needle passage of any other body member.
For a more complete understanding of the present invention, reference should now be had to the embodiments shown in the accompanying drawings and described below. In the drawings:
As used herein, the term “vascular access” is used to mean an intended surgical connection between the arterial and venous system through which blood flows from the artery to the vein. As noted above, this can be achieved by directly connecting a vein to an artery (AVF) or by utilizing a synthetic or autologous conduit to connect the arterial and venous systems (AVG). Because there are many types of AVG's and associated components that are well known in the art and that may be utilized to practice the present invention, a more detailed description of these components is not required. It is understood that the present invention is not directed to any particular type of AVG. The vascular access graft apparatus and method described herein is for use in medical procedures requiring vascular access. Accordingly, the features described herein may be used with any conventional vascular access graft including AVG's including, but not limited to, the AVG described by U.S. Pat. No. 9,585,998, the contents of which are hereby incorporated by reference herein in their entirety. A similar application is shown and described in U.S. Pub. Application No. 2014/0336682, the contents of which are also incorporated by reference herein in their entirety. Accordingly, detailed explanations of the functioning of all of the components and use of the grafts are deemed unnecessary for understanding of the present description by one of ordinary skill in the art.
Certain terminology is used herein for convenience only and is not to be taken as a limiting. For example, words such as “upper,” “lower,” “left,” “right,” “horizontal,” “vertical,” “upward,” “downward,” “top” and “bottom” merely describe the configurations shown in the FIGS. Indeed, the components may be oriented in any direction and the terminology, therefore, should be understood as encompassing such variations unless specified otherwise. The words “interior” and “exterior” refer to directions toward and away from, respectively, the geometric center of the core and designated parts thereof. The terminology includes the words specifically mentioned above, derivatives thereof and words of similar import.
Referring now to the drawings, wherein like reference numerals designate corresponding or similar elements throughout the several views, a vascular access graft for connecting an artery to a vein is shown in
An applicator device for use in identifying a needle insertion location for cannulation of an implanted vascular access graft 40 is also shown in
The applicator device can be formed of either synthetic or natural materials, including, but not limited to, thermoplastics, thermoset polymers, elastomers, rubbers, or woven or non-woven composite materials. The applicator device may be, for example, any suitable molded form of a polymeric, plastic foam (including open celled foam), woven composite or non-woven composite, mixtures thereof, or the like. In particular, a suitable applicator device may thus be prepared, for example, from Nylon, a polyolefin, such as polyethylene, including UHMW polyethylene, structural plastics such as PEEK (polyetheretherketone), polysulfone, polypropylene, ethylene propylene copolymers, and ethylene butylene copolymers, polyurethanes, polyurethane foams, polystyrenes, plasticized polyvinylchlorides, polyesters, Delrin polyacetal, and polyamides, and homopolymer and copolymers of the above. The applicator device can also be made of a gel-like substance to provide pressure for hemostasis when compressed. The applicator may be doped with one or more drugs to aid in the process of cannulation and/or removing needles. For example, Lidocaine may be added to help minimize pain of a needle stick, and/or a topical hemostatic may be incorporated to aid in the cessation of bleeding. Many combinations of drug combinations with the applicator may be expected. It is understood that the applicator device may assume a variety of shapes as necessary to accommodate and adapt to a variety of vascular access grafts and cannulation chambers. It is further understood that a needle passage may be provided where the material of the applicator device is too hard to allow penetration by the needle.
In one aspect, the applicator device 50 may be configured to be adaptable to an implanted vascular access graft 40 by fitting onto the implanted graft in the manner of a puzzle piece. In this embodiment, the “fit-on” applicator device 50 as shown in
Referring to
The applicator device 50 is manually aligned with the cannulation chamber 44 such that the legs 54 correspond to the notches 48 in the cannulation chamber 44. The applicator device 50 is then pressed in a direction toward the cannulation chamber 44 such that the legs 54 engage in the notches 48. During downward movement of the device 50 the legs 54 are slidably received in the longitudinal notches 48 in the peripheral rim 46 of the cannulation chamber 44. The applicator device 50 is thus aligned in a positioned so that the device is located over the cannulation chamber 44 as shown in
Another embodiment of a “fit-on” applicator device is shown in
In another embodiment, the vascular access graft 40 comprises one or more fixably-positioned magnetic, paramagnetic or ferromagnetic materials 70 creating one or more distinct sites on the cannulation chamber 44 as shown in
A locator or detector (not shown), including one or more magnets, may be used for locating the implanted graft and identifying the cannulation chamber 44 for needle insertion and access. The locator, or “wand”, is passed over the skin in suspected proximity to the implanted graft. The wand is used then to identify and to locate the cannulation chamber 44, or one or more sites in, on, or about the implanted graft where cannulation should optimally occur. This “localizing” ability of a magnet-containing detector can make it easier to find the proper cannulation site while minimizing damage to the vascular access graft. The cannulation chamber 44 is localizable through the skin with a high degree of accuracy and precision by passing the wand over the surface of the skin in the region proximate to the implant. This allows the user to perform needle insertion, or cannulation, to at least one or more selected locations in the port 47 region as defined by the presence of the one or more magnetic material sites. It is possible to extend this to applications for detecting the implanted AVG via an RFID tag, a concentration of specific material that would be detected by Near Infrared light/visible light spectroscopy, or other methods known in the art.
While any suitably sized magnets may be used, exemplary magnets include Neodymium Iron Boron (NdFeB) cylindrically shaped (e.g., “button”) magnets. In certain embodiments, the magnets may be coated with one or more protective layers to facilitate maximum protection and durability. Preferably, the paramagnetic material used in formation of the disclosed medical devices will include, consist essentially of, or consist of, iron, steel, cobalt, nickel, a ceramic material, surgical-grade steel, or an alloy or combination thereof. Alternatively, the material used in the formation of the disclosed medical devices may include, consist essentially of, or consist of, a superparamagnetic material, including for example, superparamagnetic metal oxide nanoparticles (e.g., superparamagnetic iron oxide nanoparticles [SPIOs] [see e.g., Ji et al. (2007)].
The number of magnet sites 70 spaced around the rim 46 of the cannulation chamber 44 may be of any practical number. It is envisioned that the vascular access graft comprises from 2 to about 8 or 10 magnetic sites placed equidistant along a substantial portion of the long axis of the graft 10. Exemplary magnets for use with the disclosed access devices, grafts, and vascular access ports will preferably include, consist essentially of, or alternatively consist of, a ceramic, lanthanoid, paramagnetic, ferrimagnetic, or ferromagnetic material, including, but not limited to, those that include aluminum, boron, cobalt, copper, iron, neodymium, nickel, samarium, titanium, or a combination or alloy thereof, including, but not limited to commercially-available permanent alloy magnets, such as, without limitation, NdFeB, AlNi, AlCoMax, AlNiCo, TiConAl, and the like.
In use, the user places the detector “wand” over the skin above the implanted vascular access graft 40. The magnets on the wand detect the magnetic sites of the surface of the cannulation chamber 44 of the implanted vascular access graft and localize it. A needle is inserted through the skin into the port 47 of the cannulation chamber 44 as identified by the wand. Localization and identification of the vascular access graft 40 following implantation is facilitated by the presence of the one or more magnetic material sites 70 included with the cannulation chamber 44.
In an alternative arrangement, a third embodiment of a fit-on applicator device is shown in
Referring now to
In another embodiment, the applicator device comprises a sheet, or sticker, as shown in
The bottom surface 94 of the sticker includes a layer of adhesive material for removably adhering the sticker to the skin 30 over the vascular access graft 40. Many types of adhesive are suitable for use with the sticker 90 as long as the adhesive allows firm bonding of the sticker 90 to the skin. The adhesive should also allow easy removal of the sticker 90 following use. The adhesive is preferably a pressure sensitive adhesive applied to the bottom surface 94 of the sticker 90. A wide variety of such adhesives are commercially available. In one embodiment, a portion of the edge of the bottom surface 94 of the sticker 90 may be devoid of adhesive to prevent that portion of the sticker from adhering to the skin 30. This configuration provides a location for a user to grasp the sticker 90 for removing the sticker from the skin 30. The adhesive material preferably does not leave any residue on the skin 30 when removed.
The sticker 90 may be any size sufficient to accommodate the cannulation chamber 44 of the vascular access graft 40, as well as providing an adhesive coated area large enough to provide a firm bond between the sticker 90 and the skin 30. In one embodiment, the sticker 90 may have an outer perimeter larger than the outer perimeter of the cannulation chamber 44 so as to fully surround the chamber when the sticker 90 is placed over the vascular access graft 40. As an alternative, only an edge region of the bottom surface 94 of the sticker 90 may be coated with the adhesive material.
The sticker 90 may further comprise a protective backing removably adhered to the bottom surface 94 of the sticker 90 over the adhesive layer. The removable protective backing prevents adhesion of the sticker 90 to undesired surfaces prior to use. Protective backings are well known in the art and typically comprise a variety of materials, such as paper treated with a release agent such as silicone, or alternatively a conformable material, for example, polyethylene, polyvinyl chloride, and the like. The removable protective backing may be the same size and shape as the sticker 90 or may be larger. In the embodiment described above, wherein the sticker 90 has a portion of the edge without adhesive, the user may grasp that portion for easily removing the backing from the sticker 90.
In use, the protective backing is manually removed from bottom surface 94 of the sticker 90 for exposing the adhesive. The sticker 90 is then ready to be affixed to the skin 30. The sticker 90 is positioned on the skin over the AVG 40 so that the opening 96 substantially surrounds the cannulation chamber 44. Once positioned, pressure is applied so that the sticker 90 is adhesively conformed to the skin 30. Once secured to the skin 30 around the cannulation chamber 44 of the vascular access graft 40, the sticker 90 will enable the user to determine a location for needle insertion. The sticker 90 thus provides an effective way of providing a means for indicating the cannulation location of an AVG.
In another embodiment, shown in
In another embodiment as shown in
An embodiment for use in combination with an applicator device for positioning the applicator device for locating a point of cannulation of an implanted AVG is shown in
Another embodiment of an apparatus and method for guiding cannulation of an arteriovenous graft using straps 112 is shown in
Referring now to
In use, the sleeve 132 is positioned on the arm with the openings over the cannulation chambers 44. The user can then cannulate the vascular access graft 40. In a further embodiment, each of the openings 134 in the sleeve 132 forms a pocket 136 with a layer of material adjacent the skin 30 (
The apparatus and method for cannulation of a vascular access graft as described herein has many advantages, including providing a reliable means for allowing a user to perform hemodialysis while consistently and accurately accessing an implanted graft site. Using an external device to identify and localize the position of the implanted device reduces incorrect cannulations, and facilitates increased patency of the vascular access graft after surgical implantation into the body. Fewer missed needle insertions and cannulation errors reduce opportunity for damaging, destroying, or displacing the implanted graft due to incorrect insertion of the cannula or improper or repeated needle sticks attempting to “hit” the proper insertion site on the subcutaneous graft. Cumulative damage inflicted by repetitive needle puncture weakens the graft wall and creates conditions for pseudoaneurysm formation. An AVG sustains roughly 300 needle sticks a year. The apparatus and method as described herein providing for needle rotation to evenly distribute the needle damage over the entire length of the graft helps minimize or delay pseudoaneurysm formation.
The present apparatus tracks the location of cannulation sites to therefore be assured that proper needle rotation is taking place. A system or sequence designed to facilitate needle rotation facilitates proper needle rotation throughout a cannulation site area by maintaining compliance with the facilitated cannulation sequence.
The invention also enhances the ability of a patient or medical personnel to properly and accurately identify the placement of the implanted vascular access grafts to ensure proper placement. The vascular access graft may be visualized by conventional medical imaging means, including, for example, x-ray, magnetic resonance imaging, and/or computer-aided tomography (CT).
Although the present invention has been shown and described in considerable detail with respect to only a few exemplary embodiments thereof, it should be understood by those skilled in the art that I do not intend to limit the invention to the embodiments since various modifications, omissions and additions may be made to the disclosed embodiments without materially departing from the novel teachings and advantages of the invention, particularly in light of the foregoing teachings. For example, the present invention is suitable for use in a number of vascular access devices and applications. Accordingly, we intend to sticker all such modifications, omission, additions and equivalents as may be included within the spirit and scope of the invention as defined by the following claims. In the claims, means-plus-function clauses are intended to sticker the structures described herein as performing the recited function and not only structural equivalents but also equivalent structures. Thus, although a nail and a screw may not be structural equivalents in that a nail employs a cylindrical surface to secure wooden parts together, whereas a screw employs a helical surface, in the environment of fastening wooden parts, a nail and a screw may be equivalent structures.
Number | Name | Date | Kind |
---|---|---|---|
1017301 | Lockwood | Feb 1912 | A |
3999504 | Kearse | Dec 1976 | A |
4004298 | Freed | Jan 1977 | A |
4121003 | Williams | Oct 1978 | A |
4228796 | Gardiner | Oct 1980 | A |
4268983 | Cook | May 1981 | A |
4619641 | Schanzer et al. | Oct 1986 | A |
4723544 | Moore et al. | Feb 1988 | A |
4733661 | Palestrant | Mar 1988 | A |
4822341 | Colone | Apr 1989 | A |
5123907 | Romaine | Jun 1992 | A |
5147307 | Gluck | Sep 1992 | A |
5167629 | Vertenstein et al. | Dec 1992 | A |
5192310 | Herweck et al. | Mar 1993 | A |
5312350 | Jacobs | May 1994 | A |
5358281 | Greig | Oct 1994 | A |
5364361 | Battenfield | Nov 1994 | A |
5633058 | Hoffer et al. | May 1997 | A |
5700287 | Myers et al. | Dec 1997 | A |
5704915 | Melsky et al. | Jan 1998 | A |
5713859 | Finch et al. | Feb 1998 | A |
5849036 | Zarate | Dec 1998 | A |
6024723 | Cota | Feb 2000 | A |
6036632 | Whitmore, III et al. | Mar 2000 | A |
6102884 | Squitieri | Aug 2000 | A |
6146414 | Gelman | Nov 2000 | A |
6261257 | Uflacker et al. | Jul 2001 | B1 |
6283942 | Staehlin et al. | Sep 2001 | B1 |
6428504 | Riaziat et al. | Aug 2002 | B1 |
6500109 | Tokita et al. | Dec 2002 | B2 |
6508786 | Huitema et al. | Jan 2003 | B2 |
6547820 | Staudenmeier | Apr 2003 | B1 |
6626865 | Prisell | Sep 2003 | B1 |
7101356 | Miller | Sep 2006 | B2 |
7108673 | Batiste | Sep 2006 | B1 |
7261705 | Edoga et al. | Aug 2007 | B2 |
7452374 | Hain et al. | Nov 2008 | B2 |
7527593 | Fidel et al. | May 2009 | B2 |
7540859 | Claude et al. | Jun 2009 | B2 |
7566317 | Batiste et al. | Jul 2009 | B1 |
7670333 | Schatzberger | Mar 2010 | B2 |
7713234 | Karanzas | May 2010 | B2 |
7722535 | Randlov et al. | May 2010 | B2 |
7740593 | Shabaz | Jun 2010 | B2 |
7762977 | Porter et al. | Jul 2010 | B2 |
7780622 | Fitzpatrick et al. | Aug 2010 | B2 |
7780662 | Bahney | Aug 2010 | B2 |
7806922 | Henderson et al. | Oct 2010 | B2 |
7828781 | Edoga et al. | Nov 2010 | B2 |
7833186 | Batiste | Nov 2010 | B1 |
8029563 | House et al. | Oct 2011 | B2 |
8066758 | Bogert et al. | Nov 2011 | B2 |
8075525 | Yang | Dec 2011 | B2 |
8105307 | Ponce | Jan 2012 | B2 |
8133201 | Hurtado | Mar 2012 | B1 |
8152751 | Roger et al. | Apr 2012 | B2 |
8162884 | Van't Hooft | Apr 2012 | B2 |
8163002 | Weinberg | Apr 2012 | B2 |
8211056 | Cull | Jul 2012 | B2 |
8414530 | Mason | Apr 2013 | B2 |
8439873 | Donovan | May 2013 | B1 |
8529525 | Gerber et al. | Sep 2013 | B2 |
8764698 | Cull | Jul 2014 | B2 |
8784359 | Plahey et al. | Jul 2014 | B2 |
8870820 | Murphy et al. | Oct 2014 | B2 |
8882694 | Li et al. | Nov 2014 | B2 |
8906087 | House et al. | Dec 2014 | B2 |
8961458 | Pesach et al. | Feb 2015 | B2 |
8992453 | Vournakis et al. | Mar 2015 | B2 |
9023051 | Hanson et al. | May 2015 | B2 |
9067026 | Stonebridge et al. | Jun 2015 | B2 |
9199044 | Bangera et al. | Dec 2015 | B2 |
9427218 | Hong et al. | Aug 2016 | B2 |
9440058 | Osborne et al. | Sep 2016 | B2 |
9585998 | Gage et al. | Mar 2017 | B2 |
9694145 | Onorato | Jul 2017 | B1 |
9700674 | Despa et al. | Jul 2017 | B2 |
9757515 | Patel | Sep 2017 | B1 |
9848860 | Hong et al. | Dec 2017 | B2 |
9907900 | Batiste et al. | Mar 2018 | B1 |
10092293 | Zilla et al. | Oct 2018 | B2 |
10149750 | Wagner et al. | Dec 2018 | B2 |
10173015 | Fiedler et al. | Jan 2019 | B2 |
10265458 | Young et al. | Apr 2019 | B2 |
10322249 | Sweis | Jun 2019 | B2 |
10420874 | Gage et al. | Sep 2019 | B2 |
10456570 | Finch, Jr. | Oct 2019 | B2 |
10568657 | Rowe | Feb 2020 | B2 |
10582997 | Edwin et al. | Mar 2020 | B2 |
10595888 | Hong et al. | Mar 2020 | B2 |
10596017 | Hong et al. | Mar 2020 | B2 |
10682453 | Gale et al. | Jun 2020 | B2 |
10695040 | Hong et al. | Jun 2020 | B2 |
10850084 | Rayhanabad | Dec 2020 | B1 |
10874842 | Bizup et al. | Dec 2020 | B2 |
10905867 | Glowczwski et al. | Feb 2021 | B2 |
10912935 | Wiley et al. | Feb 2021 | B2 |
11045339 | Gage et al. | Jun 2021 | B2 |
11065377 | Gage et al. | Jul 2021 | B2 |
11123481 | Howell et al. | Sep 2021 | B2 |
11197952 | Young et al. | Dec 2021 | B2 |
11241564 | Casiello et al. | Feb 2022 | B2 |
11553941 | Hong et al. | Jan 2023 | B2 |
11602446 | Hong et al. | Mar 2023 | B2 |
11654224 | Pillai | May 2023 | B2 |
11672681 | Syed | Jun 2023 | B2 |
11690991 | Finch, Jr. | Jul 2023 | B2 |
20030100859 | Henderson et al. | May 2003 | A1 |
20040153031 | Van Kaauwen | Aug 2004 | A1 |
20040193106 | Miller | Sep 2004 | A1 |
20040022044 | Hogendijk et al. | Nov 2004 | A1 |
20050013850 | Caers et al. | Jan 2005 | A1 |
20050148935 | Dimitrova et al. | Jul 2005 | A1 |
20050267396 | Dame | Dec 2005 | A1 |
20060118236 | House et al. | Jun 2006 | A1 |
20070123811 | Squitieri | May 2007 | A1 |
20080146963 | Crocker et al. | Jun 2008 | A1 |
20080195043 | Schwach et al. | Aug 2008 | A1 |
20080221519 | Schwach et al. | Sep 2008 | A1 |
20090209921 | Claude et al. | Aug 2009 | A1 |
20100015590 | Kiss | Jan 2010 | A1 |
20110060264 | Porter et al. | Mar 2011 | A1 |
20110202003 | Cook | Aug 2011 | A1 |
20110275930 | Cox et al. | Nov 2011 | A1 |
20110276011 | Armstrong et al. | Nov 2011 | A1 |
20120130314 | Stonebridge et al. | May 2012 | A1 |
20120245536 | Gerber et al. | Sep 2012 | A1 |
20120265138 | Harylka et al. | Oct 2012 | A1 |
20130072883 | Edoga et al. | Mar 2013 | A1 |
20130157924 | Dewhurst et al. | Jun 2013 | A1 |
20130237929 | Hong et al. | Sep 2013 | A1 |
20140018721 | Gage et al. | Jan 2014 | A1 |
20140039453 | Sonderegger | Feb 2014 | A1 |
20140128842 | Deberadine | May 2014 | A1 |
20140155819 | Amirouche et al. | Jun 2014 | A1 |
20140200515 | Patterson et al. | Jul 2014 | A1 |
20140257183 | Mica et al. | Sep 2014 | A1 |
20140324021 | Ulrich et al. | Oct 2014 | A1 |
20140336682 | Naoum | Nov 2014 | A1 |
20150223906 | O'Neill et al. | Aug 2015 | A1 |
20160136363 | Mcclellan | May 2016 | A1 |
20160310663 | Dantsker et al. | Oct 2016 | A1 |
20160310679 | Hirth | Oct 2016 | A1 |
20160354112 | Kustra et al. | Dec 2016 | A1 |
20160375193 | Farzam et al. | Dec 2016 | A1 |
20170173252 | Gage et al. | Jun 2017 | A1 |
20170203053 | Burkett | Jul 2017 | A1 |
20170304092 | Hong et al. | Oct 2017 | A1 |
20170340840 | Sweis | Nov 2017 | A1 |
20180116646 | Hong et al. | May 2018 | A1 |
20180185059 | Rowe | Jul 2018 | A1 |
20180193031 | Du et al. | Jul 2018 | A1 |
20180280605 | Gage et al. | Oct 2018 | A1 |
20180289883 | Gage et al. | Oct 2018 | A1 |
20180289901 | Boggild-Damkvist et al. | Oct 2018 | A1 |
20190070399 | Casiello et al. | Mar 2019 | A1 |
20190308004 | Saines | Oct 2019 | A1 |
20200016320 | Gage et al. | Jan 2020 | A1 |
20200129749 | Gage | Apr 2020 | A1 |
20200206002 | Hong et al. | Jul 2020 | A1 |
20200276430 | Gage et al. | Sep 2020 | A1 |
20200397420 | Hong et al. | Dec 2020 | A1 |
20210228855 | Glowczwski et al. | Jul 2021 | A1 |
20210322193 | Gage et al. | Oct 2021 | A1 |
20220305183 | Gage et al. | Sep 2022 | A1 |
20220323662 | Glowczwski et al. | Oct 2022 | A1 |
20230125293 | Deur | Apr 2023 | A1 |
20230201013 | Hong et al. | Jun 2023 | A1 |
20230302267 | Finch, Jr. | Sep 2023 | A1 |
Number | Date | Country |
---|---|---|
2011100534 | Jun 2011 | AU |
2012229032 | Jun 2015 | AU |
2693253 | Apr 2005 | CN |
2855430 | Jan 2007 | CN |
2875458 | Mar 2007 | CN |
201211361 | Mar 2009 | CN |
201596195 | Oct 2010 | CN |
201668815 | Dec 2010 | CN |
201996908 | Oct 2011 | CN |
202223661 | May 2012 | CN |
102580192 | Jul 2012 | CN |
102580193 | Jul 2012 | CN |
102580194 | Jul 2012 | CN |
102580195 | Jul 2012 | CN |
102580196 | Jul 2012 | CN |
102600532 | Jul 2012 | CN |
102600533 | Jul 2012 | CN |
102600534 | Jul 2012 | CN |
102631734 | Aug 2012 | CN |
103495244 | Jan 2014 | CN |
203389172 | Jan 2014 | CN |
203885933 | Oct 2014 | CN |
204181970 | Mar 2015 | CN |
204446835 | Jul 2015 | CN |
204619059 | Sep 2015 | CN |
204635146 | Sep 2015 | CN |
204655694 | Sep 2015 | CN |
204655695 | Sep 2015 | CN |
204655696 | Sep 2015 | CN |
204745226 | Nov 2015 | CN |
105268063 | Jan 2016 | CN |
205031669 | Feb 2016 | CN |
205360154 | Jul 2016 | CN |
205515823 | Aug 2016 | CN |
205698760 | Nov 2016 | CN |
107865990 | Apr 2018 | CN |
108114350 | Jun 2018 | CN |
108283756 | Jul 2018 | CN |
108525077 | Sep 2018 | CN |
102004037207 | Apr 2005 | DE |
1426067 | Jun 2004 | EP |
2686033 | May 2015 | EP |
2432521 | May 2017 | EP |
2544623 | Jan 2018 | EP |
3338736 | Jun 2018 | EP |
3448311 | Mar 2019 | EP |
3562424 | Nov 2019 | EP |
2980977 | Apr 2013 | FR |
2202445 | Sep 1988 | GB |
206183758 | May 2017 | IN |
2002-515798 | May 2002 | JP |
101732305 | May 2017 | KR |
8000060 | Jan 1980 | WO |
2005002661 | Jan 2005 | WO |
2011112755 | Sep 2011 | WO |
12006790 | Jan 2012 | WO |
2012125927 | Sep 2012 | WO |
13061352 | May 2013 | WO |
2016179457 | Nov 2016 | WO |
2018183854 | Oct 2018 | WO |
2018183886 | Oct 2018 | WO |
2018191121 | Oct 2018 | WO |
2020092441 | May 2020 | WO |
2022203738 | Sep 2022 | WO |
2022203739 | Sep 2022 | WO |
2023177777 | Sep 2023 | WO |
Entry |
---|
Gage, Shawn M.; Corrected Notice of Allowance for U.S. Appl. No. 15/941,599, filed Mar. 30, 2018, dated Apr. 28, 2021, 6 pgs. |
Gage, Shawn M .; Non-Final Office Action for U.S. Appl. No. 15/941,599, filed Mar. 30, 2018, dated Jan. 8, 2019, 14 pgs. |
Gage, Shawn M.; Notice of Allowance for U.S. Appl. No. 15/941,599, filed Mar. 30, 2018, dated Mar. 16, 2021, 22 pgs. |
Gage, Shawn M.; Restriction Requirement for U.S. Appl. No. 15/941,599, filed Mar. 30, 2018, dated Oct. 16, 2018, 8 pgs. |
Gage, Shawn M.; Final Office Action for U.S. Appl. No. 15/941,599, filed Mar. 30, 2018, dated Sep. 20, 2019, 29 pgs. |
Gage, Shawn M.; Restriction Requirement for U.S. Appl. No. 15/450,523, filed Mar. 6, 2017, dated Jul. 12, 2018, 9 pgs. |
Gage, Shawn M; Notice of Allowance for U.S. Appl. No. 15/450,523, filed Mar. 6, 2017, dated May 17, 2019, 7 pgs. |
Gage, Shawn M.; Non-Final Office Action for U.S. Appl. No. 15/941,790, filed Mar. 30, 2018; dated Jul. 20, 2020; 50 pgs. |
Gage, Shawn M.; Applicant-Initiated Interview Summary for U.S. Appl. No. 16/175,698, filed Oct. 30, 2018, dated Jun. 25, 2021, 3 pgs. |
Gage, Shawn M.; Final Office Action for U.S. Appl. No. 16/175,698, filed Oct. 30, 2018, dated Jan. 22, 2021, 24 pgs. |
Gage, Shawn M.; Final Office Action for U.S. Appl. No. 16/175,698, filed Oct. 30, 2018, dated Jun. 27, 2019, 18 pgs. |
Gage, Shawn M.; Non-Final Office Action for U.S. Appl. No. 16/175,698, filed Oct. 30, 2018, dated Mar. 31, 2020, 41 pgs. |
Gage, Shawn M.; Applicant Initiated Interview Summary for U.S. Appl. No. 16/175,698, filed Oct. 30, 2018, dated Oct. 24, 2019, 6 pgs. |
Gage, Shawn M.; International Search Report and Written Opinion for Application No. PCT/US2018/025414, filed Mar. 30, 2018, dated Aug. 21, 2018, 20 pgs. |
Gage, Shawn M.; Invitation to Pay Additional Fees for Application No. PCT/US2018/025414, filed Mar. 30, 2018, dated Jun. 27, 2018, 18 pgs. |
Gage, Shawn M.; International Preliminary Report on Patentability for PCT Application No. PCT/US2018/025414, filed Mar. 30, 2018, dated Oct. 10, 2019, 15 pgs. |
Gage, Shawn M.; International Preliminary Report on Patentaiblity for Application No. PCT/US2012/029449, filed Mar. 16, 2012, dated Sep. 26, 2013, 6 pgs. |
Gage, Shawn M.; International Search Report and Written Opinion for Application No. PCT/US2012/029449, filed Mar. 16, 2012, dated Oct. 29, 2012, 8 pgs. |
Gage, Shawn M.; Office Action for Australian Application No. 2012229032, filed Mar. 16, 2012, dated Feb. 9, 2015, 3 pgs. |
Gage, Shawn M.; Office Action for Canadian Application No. 2,829,766, filed Mar. 16, 2012, dated Jan. 10, 2018, 5 pgs. |
Gage, Shawn M.; Extended European Search Report for Application No. 12757046.3, filed Mar. 16, 2012, dated Jan. 3, 2014, 7 pgs. |
Gage, Shawn M.; Decision to Grant for European Application No. 12757046.3, filed Mar. 16, 2012, dated Apr. 10, 2015, 2 pgs. |
Gage, Shawn M.; Intention to Grant for European Application No. 12757046.3, filed Mar. 16, 2012, dated Nov. 19, 2014, 8 pgs. |
Gage, Shawn M.; International Search Report and Written Opinion for Application No. PCT/US2018/025456, filed Mar. 30, 2018, dated Jun. 25, 2018, 12 pgs. |
Gage, Shawn M.; International Preliminary Report on Patentability for PCT Application No. PCT/US2018/025456, filed Mar. 30, 2018; dated Oct. 10, 2019, 10 pgs. |
Gage, Shawn M.; International Preliminary Report and Patentability and Written Opinion for PCT Application No. PCT US2019/058665, filed Oct. 29, 2019, dated May 14, 2021, 10 pgs. |
Gage, Shawn M.; International Search Report and Written Opinion for PCT Application No. PCT/US2019/058665, filed Oct. 29, 2019; dated Apr. 2, 2020; 16 pgs. |
Gage, et al., “New Developments in Hemodialysis Grafts,” Endovascular Today, Jun. 2010, 5 pgs. |
Gage, Shawn M.; Non-Final Office Action for U.S. Appl. No. 16/580,423, filed Sep. 24, 2019, dated Apr. 14, 2022, 17 pgs. |
Gage, Shawn; Office Action for Japanese patent application No. 2020-502524, filed Mar. 30, 2018, dated Apr. 18, 2022, 16 pgs. |
Gage, Shawn M.; Decision to Grant for European serial No. 12757046.3, filed Mar. 16, 2012, dated Apr. 10, 2015,2 pgs. |
Gage, Shawn M.; Extended European Search Report for serial No. 12757046.3, filed Mar. 16, 2012, dated Jan. 3, 2014, 7 pgs. |
Gage, Shawn M.; Final Office Action dated Jun. 27, 2019, for U.S. Appl. No. 16/175,698, filed Oct. 30, 2018, 18 pages. |
Gage, Shawn M.; Final Office Action for U.S. Appl. No. 16/175,698, filed Oct. 30, 2018, dated Jan. 22, 2021, 24 pages. |
Gage, Shawn M.; Intention to Grant for European serial No. 12757046.3, filed Mar. 16, 2012, dated Nov. 19, 2014,8 pgs. |
Gage, Shawn M.; International Search Report and Written Opinion for PCT Application No. PCT/US2019/058665, filed Oct. 29, 2019; dated Apr. 2, 2020; 16 pages. |
Gage, Shawn M.; International Search Report and Written Opinion for serial No. PCT/US2018/025456, filed Mar. 30, 2018, dated Jun. 25, 2018, 12 pgs. |
Gage, Shawn M.; Issue Notification for U.S. Appl. No. 14/027,986, filed Sep. 16, 2013, dated Feb. 15, 2017, 1 pg. |
Gage, Shawn M.; Non-Final Office Action for U.S. Appl. No. 14/027,986, filed Sep. 16, 2013, dated Apr. 1, 2016, 13 pgs. |
Gage, Shawn M.; Non-Final Office Action for U.S. Appl. No. 15/450,523, filed Mar. 6, 2017, dated Jan. 23, 2019, 9 pgs. |
Gage, Shawn M.; Non-Final Office Action for U.S. Appl. No. 15/941,790, filed Mar. 30, 2018; dated Jul. 20, 2020; 50 pages. |
Gage, Shawn M.; Non-Final Office Action issued for U.S. Appl. No. 16/175,698, filed Oct. 30, 2018; dated Mar. 31, 2020; 41 pages. |
Gage, Shawn M.; Notice of Allowance for U.S. Appl. No. 14/027,986, filed Sep. 16, 2013, dated Nov. 2, 2016, 7 pgs. |
Gage, Shawn M.; Office Action for Australian serial No. 2012229032, filed Mar. 16, 2012, dated Feb. 9, 2015, 3 pgs. |
Gage, Shawn M.; Office Action for Canadian serial No. 2,829,766, filed Mar. 16, 2012, dated Jan. 10, 2018, 5 pgs. |
Gage, Shawn M.; Requirement for Restriction/Election for U.S. Appl. No. 15/450,523, filed Mar. 6, 2017, dated Jul. 12, 2018, 9 pgs. |
Gage, Shawn M.; Restriction Requirement for U.S. Appl. No. 14/027,986, filed Sep. 16, 2013, dated Jan. 13, 2016, 9 pgs. |
Gage, Shawn M; International Preliminary Report on Patentaiblity for serial No. PCT/US2012/029449, filed Mar. 16, 2012, dated Sep. 26, 2013, 6 pgs. |
Gage, Shawn M; International Search Report and Written Opinion for serial No. PCT/US2012/029449, filed Mar. 16, 2012, dated Oct. 29, 2012, 8 pgs. |
Gage, Shawn, Notice of Allowance for U.S. Appl. No. 15/450,523, filed Mar. 6, 2017, dated May 17, 2019, 7 pages. |
Gage, Shawn; Applicant Initiated Interview Summary for U.S. Appl. No. 16/175,698, filed Oct. 30, 2018; dated Oct. 24, 2019; 6 pages. |
Gage, Shawn; International Preliminary Report on Patentability for PCT Application No. PCT/US2018/025414, filed Mar. 30, 2018; dated Oct. 10, 2019; 14 pages. |
Innavasc Medical, Inc., International Patent Application No. PCT/US2018/025414, Invitation to Pay Additional Fees and Partial International Search Report, dated Jun. 27, 2018. |
Number | Date | Country | |
---|---|---|---|
20210346585 A1 | Nov 2021 | US |
Number | Date | Country | |
---|---|---|---|
62479791 | Mar 2017 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15941599 | Mar 2018 | US |
Child | 17379655 | US |